"We standardized immuno-oncology profiling with the IO-Panel and we firmly believe that immune categories and spatial relationships between tumor and immune cells have predictive value for treatment with IO therapies," said Dr. Florian Leiss, Director of Profiling and Diagnostics. "We are looking for scientists with clear study design and access to a relevant cohort to make the leap from hypothesis to insight. We are excited about the adoption of the IO-Panel in biopharma trials and want to empower academic collaborators to contribute to a growing data pool and to publish their findings."
The Definiens IO-Panel Exploratory Program provides both scientific and technological consulting services based on the Tissue Phenomics® methodology. This approach is closely integrated with histochemistry assay development, image analysis, multi-omics integration, and bioinformatics to reveal insights within the tissue tumor microenvironment. This is the basis for successful immune profiling, biomarker discovery, and future patient stratification.
This special research collaboration offers IO-Panel multiplex images with seven biomarkers through Definiens established lab partners as well as a comprehensive analysis and profiling using the distinct expression of immune signatures, which groups patients into one of six predefined immune categories. By reducing input variability and standardizing image analysis, the IO-Panel allows researchers to compare data across multiple studies. The selected partner will have the opportunity to publish and present their scientific findings at future conferences.
"The standardized IO-Panel represents another big step to accelerate the paradigm shift in immuno-oncology. By comprehensively profiling the cancer immune landscape, researchers now have the opportunity to identify very distinct patient subpopulations and therefore evaluate available therapy options," said Dr. Ralf Huss, Chief Medical Officer at Definiens. "There is a high medical need to shift oncology diagnostics from the current 'one test to one therapy' model to a comprehensive panel, which gives a complete picture of a patient's potential for effective treatment. The Definiens IO-Panel is leading the charge in this direction."
Candidates can submit their proposals at http://info.definiens.com/io-panel-exploratory-program until April 12, 2019. Interested parties can also get more information at Definiens Booth #2350 at the American Association of Cancer Research Annual Meeting (AACR 2019) in Atlanta, Georgia between March 31-April 3, 2019. Special terms and conditions apply.
About Definiens
Founded in 1994 by Nobel Laureate Dr. Gerd Binning, Definiens is now a leading tissue image analysis and data mining provider in the life science sector. As a pioneer in artificial intelligence (AI)-based image analysis, Definiens leverages the rich content and context in the tumor microenvironment of the patient's tissue to find biomarker signatures for robust patient stratification. This helps pave the way for personalized immunotherapy.
Definiens is a member of the AstraZeneca group and a trusted global partner for researchers in biotechnology. Additional clients include renowned biopharmaceuticals and prestigious academics, who have collectively published over 1,000 scientific papers using Definiens' products and services.
Please visit www.definiens.com and follow us on social media for the latest developments.
To see our new service solutions please check here.
Definiens IO-Panel is for research use only.
LinkedIn | Twitter | YouTube
Contact and inquiries: [email protected]
To learn more about Definiens IO-Panel, see a webinar featuring Dr. Florian Leiss.
SOURCE Definiens
Related Links
http://www.definiens.com
Share this article